Arul Chinnaiyan, MD, PhD

 Arul Chinnaiyan, MD, PhD
S P Hicks Endowed Professor of Pathology
Section Head, Michigan Center for Translational Pathology
Professor of Pathology and Professor of Urology
Medical School
[email protected]
Available to mentor
Arul Chinnaiyan, MD, PhD
Arul Chinnaiyan, MD, PhD
Professor
  • Center Memberships
  • Recent Publications

  • Manage Your Profile

    • Center Memberships
    • Center Member
      MM-PKUHSC Joint Institute
    • Center Member
      Taubman Institute
    • Center Member
      AI and Digital Health Innovation
    • Center Member
      Global REACH
    • Center Member
      Rogel Cancer Center
    • Center Member
      Center for Computational Medicine and Bioinformatics

    Recent Publications

     See All Publications
    • Additional Scholarship
      Supplementary Figures S1-S15 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms Reveals Divergent Indolent and Malignant States
      Iyer MK, Fletcher AA, Okoye JO, Shi C, Chen F, Kanu EN, Eckhoff AM, Bao M, Pasca di Magliano M, Frankel TL, Chinnaiyan AM, Nussbaum DP, Allen PJ. 2026 Jun 17; DOI:10.1158/1078-0432.32709068
    • Additional Scholarship
      Supplementary Tables S1-S9 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms Reveals Divergent Indolent and Malignant States
      Iyer MK, Fletcher AA, Okoye JO, Shi C, Chen F, Kanu EN, Eckhoff AM, Bao M, Pasca di Magliano M, Frankel TL, Chinnaiyan AM, Nussbaum DP, Allen PJ. 2026 Jun 17; DOI:10.1158/1078-0432.32709065
    • Journal Article
      Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.
      Chu S-CA, Hsiao Y, Wang C, Kyle JE, Jain R, Deng Y, Gritsenko MA, Henry LE, Lei JT, Dou Y, Tercan B, Shi Z, Gondal MN, Tsai C-F, Elizarraras JM, Chu RK, Yu F, Joshi SK, Jing X, Polasky DA, Weitz KK, Li GX, Paurus VL, Clendinen CS, Schepmoes AA, Lalli PM, Eder JG, Flores JE, Stratton KG, Pino JC, Posso C, Petyuk VA, Sagendorf TJ, Xu Y, Ibrahim OM, Moore RJ, Zhao R, Chen J, Monroe ME, Thiagarajan M, Hostetter G, Newton C, An E, Robles AI, Zhang X, Edwards NJ, Lu Y, Zhang H, Abdelhakim H, Piehowski PD, Mesri M, Smith RD, Kumar-Sinha C, Tognon CE, Dunlap J, Traer E, Ding L, Tyner JW, Chinnaiyan AM, Omenn GS, Rodland KD, Dhanasekaran SM, Gosline SJC, Nesvizhiskii AI, Zhang B, Liu T, Cieslik MP, Clinical Proteomic Tumor Analysis Consortium . Nat Cancer, 2026 Jun 12; DOI:10.1038/s43018-026-01175-6
      PMID: 42286338
    • Preprint
      A harmonized single-cell RNA-seq atlas of human localized and metastatic prostate cancers and benign tissues
      Cho H, Zhang Y, Zhou J, Daggar A, Kang S, Mannan R, Cao X, Dhanasekaran SM, Chinnaiyan AM. 2026 May 22; bioRxiv, DOI:10.64898/2026.05.18.725966
    • Preprint
      Dual-compartment engagement of STAR-family proteins SAM68 and QKI by LINC00941 sustains oncogenic fitness in RAS-driven lung cancer
      Acharya D, Tien JC-Y, Sharma A, Bhat V, Singh A, Azharuddin M, Pitchiaya S, Cao X, Veeneman BA, Dhanasekaran SM, Chaube BK, Chinnaiyan AM, Shukla S. 2026 May 16; bioRxiv, DOI:10.64898/2026.05.11.722569
    • Preprint
      Long-Read Haplotype Phasing Resolves Allelic Configuration as a Missing Layer of Precision Oncology
      Vo JN, Wu Y-M, Wang R, Pham T, Cao X, Yeung S, Park M, Kleyman-Smith Y, Teo GC, Wu A, Li A, Estill J, Kunju LP, Yang C, Robinson DR, Chinnaiyan AM. 2026 May 7; medRxiv, DOI:10.64898/2026.05.05.26351600
    • Journal Article
      IP31-02 NON-INVASIVE URINE TEST PREDICTS THE NEED FOR BIOPSY IN PATIENTS ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER: PROSPECTIVE MULTISITE VALIDATION AND COMPARISON WITH MRI
      Britton CJ, Meyers J, Moore B, Chevli K, Rayford W, Gadzinski AJ, Joseph JV, Patel P, Kasraeian A, Sethi PS, Robinson H, Assani KJ, Pierce JJ, Scarpato KR, Moses KA, Barocas DA, Chang SS, Penson DF, Ross A, Zhang Y, Siddiqui J, Singhal U, Salami SS, Morgan TM, Palapattu GS, Wei JT, Cao JT, Bala V, Oh Y, Heaton S, Zheng Y, Chinnaiyan AM, Tosoian JJ. Journal of Urology, 2026 Apr 30; 215 (5S): e660 DOI:10.1097/01.ju.0001191468.48904.a0.02
    • Journal Article
      IP49-13 MOLECULAR MARGIN EXTENT IN PROSTATE CANCER VARIES BY ERG FUSION STATUS
      Nallandhighal S, Monda S, Mannon R, Mahapatra S, Bahar P, Duan Z, Huang S, Wood A, George A, Mehra R, Chinnaiyan A, Salami S, Zaslavsky A, Palapattu G. Journal of Urology, 2026 Apr 30; 215 (5S): e1019 DOI:10.1097/01.ju.0001191580.27461.8d.13

    Featured News & Stories

         Illustration of tumor formation inside a globe as researchers look on
    Illuminate

    The Answers in the Epigenome

    Rogel Cancer Center researchers study how epigenetics regulates cancer-related genes, aiming to improve therapies, prevention strategies, and patient outcomes.
         microscope drawing yellow navy
    Health Lab

    Researchers identify new therapeutic target for neuroendocrine tumors in the gastrointestinal tract

    University of Michigan researchers have identified a new target that can suppress tumor growth. Their findings may lead to new treatment methods for gastroenteropancreatic neuroendocrine tumors.
         lots of the same fish swimming inside blue teal water
    Health Lab

    Additional testing can improve kidney cancer diagnosis

    Michigan Medicine findings suggest further investigation of FISH-negative tests for renal cell carcinoma could lead to more accurate diagnosis.
         blue and white pill being broken and dots falling out in middle
    Health Lab

    Researchers find a targeted approach to shut down prostate cancer growth

    Study shows a novel compound that degrades key proteins found in prostate cancer cells blocks oncogenic androgen receptor signaling.
         close up of microscope image lighter blue up top looks to be glowing and lower not glowing and more black
    Health Lab

    Inactivation of key pathway boosts the body’s immune response against tumors

    Immunotherapy uses the body’s immune system to recognize and destroy cancer cells. However, many patients are resistant to this therapy, which poses a challenge to their treatment. A study led by researchers from the University of Michigan showed that targeting CDK12/13 improves the effectiveness of cancer therapies.
         two foxes on grass
    Health Lab

    Study reveals mechanisms behind common mutation and prostate cancer

    A study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.